File Download
  Links for fulltext
     (May Require Subscription)

Conference Paper: Plasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene

TitlePlasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin gene
Authors
KeywordsPharmacy and pharmacology environmental studies
Toxicology and environmental safety
Issue Date2011
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO
Citation
The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146 How to Cite?
Abstract
INTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.
DescriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics
Persistent Identifierhttp://hdl.handle.net/10722/137759
ISSN
2013 Impact Factor: 2.294
2013 SCImago Journal Rankings: 0.739

 

DC FieldValueLanguage
dc.contributor.authorCheung, BMYen_US
dc.contributor.authorOng, KLen_US
dc.contributor.authorTso, AWKen_US
dc.contributor.authorLeung, RYHen_US
dc.contributor.authorCherny, SSen_US
dc.contributor.authorSham, PCen_US
dc.contributor.authorLam, THen_US
dc.contributor.authorLam, KSLen_US
dc.date.accessioned2011-08-26T14:33:02Z-
dc.date.available2011-08-26T14:33:02Z-
dc.date.issued2011en_US
dc.identifier.citationThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146en_US
dc.identifier.issn1742-7835-
dc.identifier.urihttp://hdl.handle.net/10722/137759-
dc.descriptionThis journal suppl. is Special Issue: Abstracts of the 10th Congress of the European Association for Clinical Pharmacology and Therapeutics-
dc.descriptionPosters-
dc.description.abstractINTRODUCTION: Adrenomedullin is involved in inflammation and like interleukin-6 (IL-6) and C-reactive protein (CRP), is a good biomarker of cardiovascular risk. Therefore, we studied common single nucleotide polymorphisms (SNPs) in the gene encoding adrenomedullin (ADM) and their relation with the plasma levels of adrenomedullin and other inflammatory markers. METHODS: Plasma adrenomedullin, IL-6 and CRP were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four SNPs in ADM were genotyped. RESULTS: Plasma adrenomedullin decreased with age (beta = -0.089, P = 0.049). Each tertile of plasma adrenomedullin was associated with a plasma IL-6 level 11.9% (95% CI: 2.6–20.3%) lower (beta = -0.116, P = 0.014). Plasma adrenomedullin level was not related to other clinical characteristics, including plasma CRP, fibrinogen and adiponectin levels. The four SNPs, rs3814700, rs11042725, rs34354539 and rs4910118 had minor allele frequencies of 31.1%, 28.7%, 33.8% and 23.4% respectively. Carriers of the minor allele of rs4910118 had plasma adrenomedullin level 10.5% (95% CI: 2.5–17.8%) lower than the non-carriers (beta = -0.115, P = 0.011). Haplotype analysis revealed a similar significant association with plasma adrenomedullin (overall P = 0.040). CONCLUSIONS: Plasma adrenomedullin is related to IL-6 but not CRP, which is consistent with the ability of adrenomedullin to stimulate IL-6 production in vitro. Plasma adrenomedullin is also influenced by a common polymorphism, which means that including the genotype may improve cardiovascular risk prediction.-
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PTO-
dc.relation.ispartofBasic & Clinical Pharmacology & Toxicologyen_US
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectPharmacy and pharmacology environmental studies-
dc.subjectToxicology and environmental safety-
dc.titlePlasma adrenomedullin level is related to plasma interleukin-6 and a polymorphism in the adrenomedullin geneen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheung, BMY: mycheung@hku.hken_US
dc.identifier.emailOng, KL: okl2000@hku.hken_US
dc.identifier.emailTso, AWK: awktso@hku.hken_US
dc.identifier.emailLeung, RYH: yhleung@hkucc.hku.hken_US
dc.identifier.emailCherny, SS: cherny@hku.hken_US
dc.identifier.emailSham, PC: pcsham@hku.hken_US
dc.identifier.emailLam, TH: hrmrlth@hkucc.hku.hken_US
dc.identifier.emailLam, KSL: ksllam@hku.hken_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.identifier.authorityTso, AWK=rp00535en_US
dc.identifier.authorityCherny, SS=rp00232en_US
dc.identifier.authoritySham, PC=rp00459en_US
dc.identifier.authorityLam, TH=rp00326en_US
dc.identifier.authorityLam, KSL=rp00343en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1742-7843.2011.00722.x-
dc.identifier.hkuros189576en_US
dc.identifier.volume109en_US
dc.identifier.issuesuppl. s1en_US
dc.identifier.spage102en_US
dc.identifier.epage103en_US
dc.publisher.placeUnited Kingdom-
dc.description.otherThe 10th Congress of the European Association for Clinical Pharmacology and Therapeutics, Budapest, Hungary, 26-29 June 2011. In Basic & Clinical Pharmacology & Toxicology, 2011, v. 109 suppl. s1, p. 102-103, abstract no. P146-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats